All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Professor Gilles Salles from Lyon University, Lyon, FR and colleagues, recently published in the Clinical Lymphoma, Myeloma & Leukemia the results of a phase II trial that investigated the efficacy and safety of daratumumab monotherapy in relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) patients.
Daratumumab is a CD38 monoclonal antibody, which has been approved for the treatment of newly-diagnosed multiple myeloma and has shown promising activity in pre-clinical NHL models. The aim of this global, proof-of-concept, phase II trial (NCT02413489) was to investigate whether single-agent daratumumab is efficient and safe for R/R mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL) patients. The primary endpoint of the trial was overall response rate (ORR). Secondary endpoints, included safety and pharmacokinetics.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox